Welcome Guest
Sign In
Register
Products
Popular Categories
Antibody Search
ELISA Kit Search
Biomolecules
Flow Cytometers
Thermal Cyclers
Microscopes
Transfection Reagents
Featured Products
New Products
Research Areas
ELISA
Western Blot
3D Cell Culture
Digital PCR
Quantitative PCR
Cell and Gene Therapy
In Vivo Models
Resources
eBooks
Bench Tips
Tech Insights
Editorial Articles
News
Product Reviews
Future Lab
White Papers
Infographics
Events
Promotions
Multimedia
Biocompare Webinars
Technologies Transforming Precision Medicine
Immunotherapy
Reproducibility
Transformative Technologies
Podcasts
Bench Tip Videos
All Videos and Webinars
Life Science Webinars
Write a Review
Antibodies
Kits/Reagents
Equipment
Services
Register
Sign In
Biocompare
Products
Protein Biochemistry
Chemicals and Reagents
POM 1
Supplier Images
POM 1 Chemicals
POM 1 from Santa Cruz Biotechnology, Inc.
Be the first to write a review!
Citations:
(12)
Supplier Page
Supplier Page from
Santa Cruz Biotechnology, Inc. for
POM 1
Description
POM 1
Product Specs
Company Info
Citations
Reviews
Product Specs
Item
POM 1
Company
Santa Cruz Biotechnology, Inc.
Price
$163.00
Supplier Page
View Company Product Page
Catalog Number
sc-203205
Quantity
50 g
Type
Biochemical Reagents
Molecular Weight
2986.13
Add to Compare List
Santa Cruz Biotechnology, Inc.
10410 Finnell Street
Dallas
,
Texas
75220
United States
Phone
: 1-800-457-3801
831-457-3801
Company Profile
Website:
http://www.scbt.com/
Citations (12)
(1)
CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells
Cell reports. Medicine
August 15, 2023
Zhang Y, Hu J, Ji K, Jiang S, Dong Y, Sun L, Wang J, Hu G, Chen D, Chen K,
et al
.
(2)
Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment
Nature communications
November 8, 2022
Liu L, Hou Y, Deng C, Tao Z, Chen Z, Hu J, Chen K.
(3)
Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells
Biochemical and biophysical research communications
April 23, 2022
Scheffel TB, Rockenbach L, Cruz FF, Kist LW, Bogo MR, Scholl JN, Figueiró F, Lenz G, Morrone FB.
(4)
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells
Cancer cell
December 13, 2021
Xue G, Zheng N, Fang J, Jin G, Li X, Dotti G, Yi Q, Lu Y.
R&D Systems
. eATP signaling
inhibitor
Suramin (Catalog#
sc-200833
),
CD39
inhibitor
POM-1
(Catalog#
sc-203205
) and NF-κB
inhibitor
QNZ
(Catalog#
sc-200675
) were purchased from
Santa Cruz Biotechnology
. Method
(5)
Extracellular vesicles regulate purinergic signaling and epithelial sodium channel expression in renal collecting duct cells
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
May 1, 2021
Barros Lamus ER, Carotti V, de Vries CRS, Witsel F, Arntz OJ, van de Loo FAJ, Carvajal CA, Bindels RJM, Hoenderop JGJ, Rigalli JP.
(6)
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia
Cancer discovery
October 1, 2020
Aroua N, Boet E, Ghisi M, Nicolau-Travers ML, Saland E, Gwilliam R, de Toni F, Hosseini M, Mouchel PL, Farge T,
et al
.
(7)
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Journal for immunotherapy of cancer
May 1, 2020
Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, Kusnierczyk A, Slupphaug G, Standal T, Waage A,
et al
.
(8)
Use of Tregs as a cell-based therapy via CD39 for benign prostate hyperplasia with inflammation
Journal of cellular and molecular medicine
May 1, 2020
Jin X, Lin T, Yang G, Cai H, Tang B, Liao X, Li H, Chen X, Gong L, Xu H,
et al
.
(9)
The role of NK cells and CD39 in the immunological control of tumor metastases
Oncoimmunology
January 1, 2019
Zhang H, Vijayan D, Li XY, Robson SC, Geetha N, Teng MWL, Smyth MJ.
(10)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Cell
November 1, 2018
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M,
et al
.
100μg/dose were i.p. injected every 3 days.
POM-1
(polyoxometalate-1) 5mg/kg/day (
Santa Cruz Biotechnology
;
sc-203205
), a
CD39
inhibitor
, was i.p. injected on a daily basis, starting on day 4 post transplantation. METHOD
(11)
γδ T Cells Protect the Liver and Lungs of Mice from Autoimmunity Induced by Scurfy Lymphocytes
Journal of immunology (Baltimore, Md. : 1950)
February 15, 2016
Ujiie H, Shevach EM.
(12)
Sesamin protects against renal ischemia reperfusion injury by promoting CD39-adenosine-A2AR signal pathway in mice
American journal of translational research
January 1, 2016
Li K, Gong X, Kuang G, Jiang R, Wan J, Wang B.
<<
<
>
>>
Reviews
Be the First to Write a Review!
POM 1 from Santa Cruz Biotechnology, Inc.
Supplier Page
View Company Product Page
$163.00
Product Specs
Company Info
Citations
Reviews
Back To Top